What antitrust review applies to MedTech M&A transactions?

US transactions above the size-of-transaction threshold set annually under the Hart-Scott-Rodino Act (updated periodically, with the threshold around $119.5 million as of 2024) must be reported to the FTC and DOJ and are subject to a waiting period before closing, while cross-border deals may also trigger European Commission review under the EU Merger Regulation if EU-relevant thresholds are met. Companies planning a sale should build HSR and, where relevant, EU merger clearance timelines into deal planning rather than treating them as a closing formality.

How do MedTech M&A valuation multiples typically vary by company stage and growth profile?

Established, profitable MedTech targets typically transact at roughly 4 to 8 times revenue, while high-growth platform technologies can command 6 to 15 times revenue or milestone-based earn-out structures, and pre-revenue companies are generally valued on a probability-weighted estimate of future revenue rather than a revenue multiple at all. Understanding which valuation framework applies to a given company's stage is essential before entering sale negotiations.

What is the most common mistake sellers make in structuring MedTech M&A deal consideration?

Accepting a high headline purchase price that is weighted heavily toward earn-outs or contingent value rights without carefully negotiated post-close operating covenants is a frequent and costly mistake, because buyers can, intentionally or not, deprioritize the specific program or milestone that triggers the contingent payment once the deal has closed. Sellers should negotiate for control or influence over the operating decisions that drive earn-out achievement, not just the size of the contingent payment.

Back to Founder & Investor Primer

Investment & FinanceStartup LifecycleM&A

Mergers and Acquisitions

Transactions in which one company acquires or combines with another, the dominant MedTech exit path, typically a strategic acquisition by an established player.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

Mergers and Acquisitions (M&A) is the umbrella term for transactions where one company acquires or combines with another via stock purchase, asset purchase, merger, or tender offer. In MedTech, strategic acquisitions by established players (Medtronic, J&J MedTech, Boston Scientific, Stryker, Abbott, Edwards) account for the large majority of venture exits. Deal structures commonly include upfront cash, contingent value rights (CVRs) tied to FDA approval or revenue milestones, and earn-outs.

What the regulation says

Antitrust review by FTC and DOJ under the Hart-Scott-Rodino Act (currently 2024 size-of-transaction threshold $119.5M, indexed annually). EU Merger Regulation review by the European Commission for qualifying transactions.

What this means in practice

MedTech M&A multiples vary widely by category: 4-8x revenue is typical for established players; 6-15x revenue or milestone-based earn-outs for high-growth platforms; pre-revenue deals are valued on probability-weighted future revenue.

Examples

A small, innovative MedTech startup specializing in a novel surgical device was acquired by a larger medical device conglomerate to expand its product portfolio and market reach.
Two mid-sized MedTech companies, each strong in different diagnostic areas, merged to create a more comprehensive offering and achieve greater operational efficiencies.
A pharmaceutical giant acquired a MedTech firm developing a drug-delivery system, integrating the technology into its pipeline to enhance therapeutic outcomes.

Common pitfalls

•Accepting a high headline price weighted heavily toward earn-outs that buyers can disincentivize post-close.
•Skipping pre-clearance HSR analysis on cross-border or category-leading deals.

Frequently asked questions

Strategic acquisitions by established players account for the large majority of MedTech venture exits because established acquirers can absorb regulatory and commercial risk, provide existing sales infrastructure, and often pay premiums for platform technology, whereas the IPO path requires sustained public market appetite and either commercial revenue or near-term FDA decision catalysts that many companies never reach on an acceptable timeline. This dynamic makes M&A readiness, including clean IP, regulatory files, and quality systems, a near-constant strategic consideration from an early stage.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Exit Multiple

Valuation ratio applied at exit, e.g., enterprise value to revenue.

Investment & Finance

Strategic Investor

Corporate investor with operational, not just financial, motives.

Investment & Finance

Due Diligence

Investigation of a company before an investment, financing, or acquisition.

Investment & Finance

Initial Public Offering(IPO)

First sale of a company's stock to public investors via a registered SEC offering, typically on NYSE or Nasdaq.

Founder & Investor Primer

· From this learning path

Investment & Finance

Capitalization Table(Cap Table)

Ledger of all securities issued by a company and who owns them.

Investment & Finance

Convertible Note

Short-term debt that converts into equity at a future financing round.

Investment & Finance

Series A / B / C Financing Rounds

Sequential priced equity rounds in venture-backed companies, typically progressing from product-market validation (A) to scale (B) to growth (C+).

Investment & Finance

Term Sheet

Non-binding outline of the key economic and control terms of an investment.

Cited by

Where this term appears across MedTech Terms.

Learning paths (1)

Founder & Investor PrimerLesson 14 of 16

Ecosystems (1)

Startup Lifecycle

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FTC·1PitchBook·1NVCA·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Acronym: M&A
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Transactions in which one company acquires or combines with another, the dominant MedTech exit path, typically a strategic acquisition by an established player.

·In MedTech, strategic acquisitions by established players (Medtronic, J&J MedTech, Boston Scientific, Stryker, Abbott, Edwards) account for the large majority of venture exits.
·Deal structures commonly include upfront cash, contingent value rights (CVRs) tied to FDA approval or revenue milestones, and earn-outs.

Remember this

Watch out: Accepting a high headline price weighted heavily toward earn-outs that buyers can disincentivize post-close.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms